Pharmacokinetics, brain distribution, and plasma protein binding of the antiepileptic drug lacosamide in rats
- 31 December 2011
- journal article
- Published by Springer Nature in Archives of Pharmacal Research
- Vol. 34 (12) , 2059-2064
Abstract
The study aimed to characterize the pharmacokinetics of lacosamide, a new antiepileptic drug, in rats after intravenous and oral administration at doses of 1, 3, 10, and 30 mg/kg. Moreover, brain distribution and plasma protein binding were estimated. After intravenous injection, terminal half-life, systemic clearance, and steady state volumes of distribution remained unaltered as a function of dose with values in the range 3.01–3.53 h, 221–241 mL/h/kg and 702–732 mL/kg, respectively. Following oral administration, absolute oral bioavailability was not dose dependent and was at 93.3–106%. However, the time to peak concentration and the dose-normalized peak concentration for 30 mg/kg were significantly different with those for other doses. The extent of urinary excretion of lacosamide was 17.1% and 16.5% for intravenous and oral doses, respectively, whereas fecal excretion was negligible. The brain to plasma ratio of lacosamide was consistent regardless of post-dosing time and the brain to plasma partition coefficient was 0.553. Further, the plasma protein binding of lacosamide was concentration independent with free fraction at 95.9%. Lacosamide showed linear pharmacokinetics at an intravenous dose of 1–30 mg/kg and an oral dose of 1–10 mg/kg but non-linear pharmacokinetics at a 30 mg/kg oral dose.Keywords
This publication has 12 references indexed in Scilit:
- Liquid chromatography–tandem mass spectrometry for quantification of lacosamide, an antiepileptic drug, in rat plasma and its application to pharmacokinetic studyBiomedical Chromatography, 2011
- Adjunctive lacosamide for partial‐onset seizures: Efficacy and safety results from a randomized controlled trialEpilepsia, 2009
- Lacosamide: pharmacology, mechanisms of action and pooled efficacy and safety data in partial-onset seizuresExpert Review of Neurotherapeutics, 2009
- LacosamideDrugs, 2009
- The Investigational Anticonvulsant Lacosamide Selectively Enhances Slow Inactivation of Voltage-Gated Sodium ChannelsMolecular Pharmacology, 2008
- Lacosamide: A Review of Preclinical PropertiesCNS Drug Reviews, 2007
- LacosamideNeurotherapeutics, 2007
- Seeking a mechanism of action for the novel anticonvulsant lacosamideNeuropharmacology, 2006
- Low drug-interaction potential of LacosamideThe Journal of Pain, 2005
- The clinical impact of new antiepileptic drugs after a decade of use in epilepsyEpilepsy Research, 2002